Actively Recruiting
Phase Ib Study of HS-20093 and HRS-5041 Combination Therapy for Men With Advanced Prostate Cancer
Led by Hansoh BioMedical R&D Company · Updated on 2025-12-05
63
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the combination of HS-20093, a humanized antibody-drug conjugate targeting B7-H3 on solid tumor cells, and HRS-5041, a PROTAC that targets androgen receptors, in patients with advanced prostate cancer who have progressed after hormonal therapy. This phase Ib, open-label, multi-center study focuses on assessing the safety, tolerability, and how the body processes these drugs in this patient group. Participants will receive HS-20093 intravenously every three weeks at the recommended phase 2 dose and HRS-5041 orally once daily in 21-day cycles. Treatment continues until unacceptable side effects or confirmed disease progression occur. The study includes dose escalation to find the maximum tolerated or administered dose within 21 days after the first dose. During the study, participants will be closely monitored for side effects and drug levels up to 24 months. Researchers will evaluate tumor response using specific criteria, prostate-specific antigen levels, and duration of response. Safety assessments include adverse event tracking up to 30 or 90 days after treatment ends, depending on the drug. Participants overall health and organ functions will be regularly checked throughout the study.
CONDITIONS
Brief Title
Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here